🔥 Friday 29 August 2025 Fri, 29 Aug 2025

Investor Centre Limited delays its 2025 Annual Report following the liquidation of key funder Amram Corp, triggering a likely trading suspension.

BSA Limited reported a 65% drop in net profit for FY2025 despite a 12% revenue increase, driven by the loss of key contracts and a significant operational overhaul. The company faces near-term unprofitable trading but maintains a strong cash position as it reshapes its business.

Livium Ltd reports a maiden profit at its battery recycling arm Envirostream, advances its lithium extraction joint venture with Mineral Resources, and secures a $30 million grant for its lithium ferro phosphate demonstration plant.

Spacetalk Ltd reports a successful FY25 transformation with revenue up 12%, losses narrowing by 57%, and a new software-led platform set to fuel scalable subscription growth.

Energy Action Limited reported a robust FY25 with a 12% revenue increase and a 247% jump in statutory profit, underpinned by disciplined expense management and contract growth.

SenSen Networks has reported a strong financial turnaround in FY2025, driven by rapid expansion in North America and innovative AI kerb enforcement technology. The company’s improved margins and positive cash flow signal a promising outlook for its Smart Cities strategy.

Aerometrex reported a mixed FY25 with strong MetroMap subscription growth boosting EBITDA despite a decline in LiDAR revenue. The company also appointed Robert Veitch as CEO, signaling a strategic focus on SaaS expansion and diversified geospatial solutions.

Dexus has announced its 18.0 cents per security distribution for the first half of 2025, alongside robust full-year results that highlight a resilient portfolio and disciplined capital management. The company signals confidence with a steady outlook despite ongoing economic uncertainty.

Carbonxt Group Limited reported a 7.1% revenue increase and a significant EBITDA improvement in FY25, while commissioning delays at its Kentucky facility temper near-term optimism.

Spacetalk Ltd reported a transformative FY25 with a 25% increase in annual recurring revenue and a significant narrowing of losses, underpinned by strong subscriber growth and a strategic debt restructuring.

Resonance Health reports robust FY25 results with 29% revenue growth and outlines ambitious FY26 guidance targeting $17 million in revenue and $2 million EBITDA. The company’s transformation into three profit-generating segments underpins its expanding footprint in the global clinical trial ecosystem.

Blue Energy Limited has successfully raised $3.2 million through a two-tranche placement, complemented by a proposed $250,000 share purchase plan, to fund drilling and pipeline development in Queensland’s North Bowen Basin.

HighCom Limited reports a sharp 90% reduction in net loss for FY25, turning EBITDA positive and advancing new product development with XTclave technology. Leadership changes and strategic focus set the stage for growth despite cautious US market conditions.

Staude Capital Global Value Fund Limited (GVF) reported a robust FY2025 with a 15.8% rise in adjusted pre-tax NTA and a fully franked dividend of 3.3 cents per share, underpinned by its discount capture strategy.

Staude Capital Global Value Fund Limited reported a 21% increase in net profit after tax for FY2025, driven by strong portfolio returns and a successful discount capture strategy. The company also declared a fully franked final dividend of 3.3 cents per share and completed a $16.9 million wholesale placement.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.

MedAdvisor Limited reported a staggering $60.2 million loss for FY25, driven by operational challenges and asset impairments, while divesting its ANZ business and becoming debt-free.

4DMedical reports a robust 56% revenue increase in FY2025, driven by SaaS expansion and strategic partnerships, while advancing FDA clearance for its innovative CT – VQ™ lung imaging software.

betr Entertainment has lodged a formal application with the Takeovers Panel, contesting PointsBet’s board decision to accelerate vesting of performance rights amid competing takeover bids, a move that significantly boosted MIXI’s voting power.

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.

Immuron Ltd reported a robust 49% increase in FY25 global sales, driven by strong Travelan® growth, while gearing up for a ProIBS launch and pivotal FDA meetings in 2025-26.

Finexia Financial Group's shares have been suspended from trading pending a significant announcement related to media speculation and a potential material acquisition.